Progressing Ahead in 2019

Summers are never slow at Roosevelt, and now we’re gearing up for an even busier fall. At the top of our to-do list is explaining how and why the public sector must make big investments to tackle our nation’s toughest challenges; promoting our ideas to influence the Democratic presidential debate; and welcoming two new fellows

At least a quarter of the 2.3 million incarcerated people in US are addicted to opioids. The fact that our criminal justice system does not routinely provide treatment for opioid withdrawal or treat addiction as a disease is at best wasteful and counterproductive. Harsh drug laws ensure that we continue to see addiction as a

FOR IMMEDIATE RELEASE: July 24, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org Roosevelt Network Launches Annual Emerging Fellows Research Program New student-led research focuses on climate change, social justice, and the opioid epidemic Today, the Roosevelt Network launched the latest research papers from its Emerging Fellowship program, a yearlong opportunity for college students to dig deeper into

The Roosevelt Network’s Emerging Fellowship program is a yearlong opportunity for college students to dig deeper into formal policy research and advocacy efforts. This year, the University of Georgia’s Tarun Ramesh and Northeastern University’s Karl Meakin tackled some of the most pressing issues of our time: the opioid crisis and climate change.  In “Incorporation of

FOR IMMEDIATE RELEASE: July 11, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org Rising Number of Hospital Mergers and Closures in Rural America Hurting Women’s Health, Economic Well-Being Roosevelt Institute documents adverse effects of market power crisis An issue brief released today by the Roosevelt Institute finds that corporate consolidation within America’s rural hospital sector is harming both

Structural problems in the health care and hospital industries are specifically hurting women in rural America, both as patients and as workers. In a new Roosevelt issue brief, Andrea Flynn, Rakeen Mabud, and Emma Chessen explore some of the industry-wide shifts that have occurred in rural areas over the last several decades. They then describe the

Growing up as a Bengali American woman in Arizona, I have repeatedly been left with an unshakable feeling of being an outsider looking in. Belonging to the only Muslim family in my small community, I struggled to relate to my peers. I can recall being forced to navigate a variety of stereotypes and constantly fielding

FOR IMMEDIATE RELEASE: June 19, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org The High Cost of Shareholder Power in Big Pharma New Roosevelt brief illustrates the magnitude of Big Pharma spending on shareholders NEW YORK, NY – At a time when Americans pay record prices for medications, pharmaceutical companies generate record profits devoted largely to rewarding shareholders

Despite Big Pharma’s claim that high-cost medicines are the price society must pay for innovation, recent research provides ample evidence that overpriced medicines are not necessary for the industry to find cures or revolutionize. Rather, high-cost and low-quality medicines are the price patients pay for an industry that prioritizes profit-seeking over public health. Like all

In “The Cost of Capture: How the Pharmaceutical Industry Has Corrupted Policymakers and Harmed Patients,” Roosevelt Fellow Julie Margetta Morgan and Advocacy Associate Devin Duffy explore how drug companies influence policymakers and what this means for patients, the American health care system, and our economy. One of a series on Big Pharma, this issue brief